Always Get the Latest Information
Part of USPPG's value is found in the service the group provides to its members. In that regard, USPPG is committed to communicating important information to its members electronically by way of timely email blasts. This includes general announcements as well as proprietary information for members only.
To receive these alerts, it is vital USPPG has your email address. Current USPPG members click here to update your contact information and include an email address.
Already a member? Click here to log in.
Lost or forgot your password? Retrieve your password, click here.
Current USPPG members click here to update your contact information.
For current information on GSK adult and pediatric pricing, view our GSK Adult & Pediatric Vaccine Price List.
For current details on GSK performance rebates, view our GSK Performance Rebate Information.
PRODUCT UPDATE
GlaxoSmithKline recently announced that the U.S. Food & Drug Administration (FDA) has approved Cervarix [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant) for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women from 10 through 25 years of age.
More information about GSK's Cervarix vaccine can be found by clicking on the product logo above or go to www.cervarix.com. For information about other GSK vaccines, visit www.gskvaccines.com.
If you are a USPPG member, please login and visit the Products section to review current contract pricing. If you wish to be a USPPG member, please click here to register.
Posted: 3/7/10
GlaxoSmithKline's Fluarix® Vaccine is Now Available for Children 3 Years of Age and Older
GSK's FLUARIX vaccine, indicated for active immunization for the prevention of disease caused by influenza virus subtypes A and type B, is now FDA approved for use in children 3 years of age and older.
Need information about Flurarix, including the immunogenicity and safety details, visit www.fluraix.com or click the Fluarix logo above.
Details on USPPG's current contract prices and rebates is now available on this website. If you are a USPPG member, please login and visit the Products section. If you wish to be a USPPG member, please click here to register.
Posted: 3/7/10
GSK's Hiberix® Vaccine Receives Approval as a Booster Dose for the Prevention of Hib Infection
In August 2009, Glaxo SmithKline received approval from the U.S. Food & Drug Administration (FDA) for Hiberix as a booster for the prevention of invasive disease caused by Haemophilus Influenzae Type b (Hib). Hiberix can be used in children 15 months to 4 years of age (prior to fifth birthday). Hiberix is currently available in 0.5mL/dose vials accompanied by pre-filled syringes. This approval, in response to a U.S. shortage of a vaccine to protect infants from Haemophilus infuenzae Type B (Hib), ensures that there is now an adequate Hib vaccine supply during necessary catch-up vaccinations.
To obtain more information about Hiberix, the product's immunogenicity and safety details, please visit www.hiberix.com or click the Hiberix logo above.
Details on USPPG's current contract prices and rebates is now available on this website. If you are a USPPG member, please login and visit the Products section. If you wish to be a USPPG member, please click here to register.
Posted: 9/16/09
FDA Approves GlaxoSmithKline's BOOSTRIX® Vaccine for Adults and Expands its Use Among Individuals 10-64 Years
GlaxoSmithKline (www.gskvaccines.com) announced that the U.S. Food and Drug Administration (FDA) has cleared the use of BOOSTRIX® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in adults 19 to 64 years of age. This approval also extends the vaccine's use as a booster protection against whooping cough in adolescents to adults 10 to 64 years of age.
For more detailed information about BOOSTRIX®, and important safety information, visit www.boostrix.com. For information about other GSK vaccines, visit www.gskvaccines.com.